Form 4/A for MNPR Monopar Therapeutics
Accepted 2026-08-28 20:18:00 ET · period of report 2026-08-26 · accession 0001437749-26-029235 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMAT | 2026-08-28 20:18 | 2026-08-26 | MNPR | Tsuchimoto Kim R | Dir | M - OptEx | $22.04 | +4,090 | 4,090 | New | +$90.1K |
| DMAT | 2026-08-28 20:18 | 2026-08-26 | MNPR | Tsuchimoto Kim R | Dir | S - Sale+OE | $111.39 | -4,090 | 0 | -100% | -$455.6K |
| DMAT | 2026-08-28 20:18 | 2026-08-26 | MNPR | Tsuchimoto Kim R | Dir | M - OptEx | $0.00 | +4,090 | 8,140 | +101% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-26 | M | A | 2,055 | $30.00 | 2,055 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. |
| 2 | Common | Common Stock | 2026-08-26 | M | A | 2,035 | $14.00 | 4,090 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. |
| 3 | Common | Common Stock | 2026-08-26 | S | D | 485 | $108.83 | 3,605 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. |
| 4 | Common | Common Stock | 2026-08-26 | S | D | 615 | $109.56 | 2,990 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. |
| 5 | Common | Common Stock | 2026-08-26 | S | D | 700 | $110.65 | 2,290 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. |
| 6 | Common | Common Stock | 2026-08-26 | S | D | 1,098 | $111.84 | 1,192 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. |
| 7 | Common | Common Stock | 2026-08-26 | S | D | 602 | $112.93 | 590 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. (F8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. |
| 8 | Common | Common Stock | 2026-08-26 | S | D | 590 | $113.84 | 0 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. (F9) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. |
| 9 | Derivative | Stock Option | 2026-08-26 | M | A | 2,055 | $0.00 | 6,165 | D | $30.00 · — to 2028-08-27 | 2,055 Common Stock | (F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. (F2) On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. |
| 10 | Derivative | Stock Option | 2026-08-26 | M | A | 2,035 | $0.00 | 8,140 | D | $14.00 · — to 2029-06-30 | 2,035 Common Stock | (F1) This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. (F3) On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. |